

Benitec Appointments

3 January 2007, Melbourne, Australia: The Directors of Benitec Limited are delighted to announce that the Company has appointed John Rawling as Co-Company Secretary and Accountant.

Mr Rawling is a chartered accountant with more than 20 years experience in the chartered accounting profession, statutory corporations and international and ASX listed companies. He is currently also Company Secretary and CFO of EQiTX Limited and previously held that position at Kentor Gold Ltd and Terrain Australia Ltd.

The Directors are also delighted to announce the appointment of Dr John Morrison to the position of Business Development and Licensing Manager.

Dr Morrison completed his PhD in protein chemistry. Post-doctoral studies in the UK and USA included work on heart disease, lipid chemistry, molecular biology, mouse genetics and genomics. While in the USA he was associated with a number of commercial projects with companies such as Life Technologies, COR Pharmaceuticals and Amgen. Returning to Australia he established a research group focused on the modulation of reproductive processes at Monash University. In 2001, he was founder and Chief Scientist of CopyRat Pty Ltd. As CSO he successfully raised two rounds of private capital, was awarded a variety of commercial grants and managed the science and intellectual property of the company. For most of 2006, Dr Morrison was a business development consultant at Biocomm Services where he assisted in all aspects of business development, including licensing, market research and strategic planning for new ventures.

"These appointments further strengthen the Benitec team and put us in an excellent position to rebuild shareholder value in 2007 and beyond" said Sue MacLeman CEO Benitec Ltd.

CONTACT:

BENITEC LTD

Sue MacLeman
Chief Executive Officer
+61 437 211 200

Rudi Michelson
Monsoon Communications
+61 411 402 737

About Benitec

Benitec is an Australian biotechnology company focused on licensing its extensive intellectual property portfolio and developing therapeutics to treat serious diseases using its proprietary ddRNAi technology. Its current therapeutic program is focused on Human Immunodeficiency Virus (HIV). Benitec's RNA-based HIV therapeutic, co-developed with the Center for Biomedicine & Genetics at the City of Hope in Los Angeles, California, will enter Phase I clinical trials in early 2007. For additional information, please visit www.benitec.com.

Forward-looking Statements

This press release contains forward-looking statements that reflect the Company's current expectations regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including the success of the Company's research strategy, the applicability of the discoveries made therein, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process.